You just read:

Biohaven Licenses Rights From Rutgers University To Develop And Commercialize Glutamate Modulating Agents In Cancer Treatment

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

03 Oct, 2016, 03:00 ET